BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» MD Anderson and C-Biomex partner to advance radioligand therapy
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
MD Anderson and C-Biomex partner to advance radioligand therapy
Feb. 8, 2024
No Comments
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. have announced a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
BioWorld Science
Collaboration
Cancer